Research and Development (R&D)

Statement, September 2018

South Centre Statement for the Informal Consultation on the Roadmap on Access to Medicines

The draft roadmap is an important work in progress that needs to be further detailed with clear deliverables and timelines. The roadmap will need to ensure complementarity of its work and the implementation of the Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPOA).

(more…)

Research Paper 86, September 2018

US’ Section 301 Actions: Why They are Illegitimate and Misguided

This research paper examines the US’ Section 301 unilateral actions against China, stemming from the US’ concerns over China’s ambitious industrial policies and its rapid technological advancements. It outlines the accusations of the US regarding China’s conditions for technology transfer and what the US sees as overly intrusive Chinese government involvement in investments. It looks in detail at why the US’ actions are in fact illegitimate and misguided. (more…)

Pager, 24 August 2018

US’ Section 301 Actions are Illegitimate and Misguided

On 23rd August, the US Administration imposed yet another set of discriminatory tariffs on China under its Section 301 Trade Act covering US$16 billion of its imports from China. This is in addition to the additional tariffs imposed on 6 July 2018 on US$34 billion of its imports from China. According to the US, these actions are supposedly because of China’s unreasonable or discriminatory practices relating to technology transfer, intellectual property and innovation.

(more…)

Policy Brief 50, August 2018

The International Debate on Generic Medicines of Biological Origin

The debate on generic medicines is not new. What makes it different today is that attacks levelled against biological generic products are couched in even more “technical” and abstruse language. The high price of biological drugs stems mainly from the introduction of barriers to the entry of generics into the market. In any debate on the feasibility of producing biological generic products identical to the ‘original’ ones, it should be made clear that what are at stake are not identical products but therapeutic equivalents.

(more…)

SC Conference on Biomedical R&D for Public Health in India, 13-14 August 2018

Title:                Conference on Biomedical R&D for Public Health in India

Date:                13-14 August 2018

Venue:              Vivanta Ambassador Hotel, New Delhi, India 

Organizers:     The South Centre, the Council for Scientific and Industrial Research, the Pharmaceuticals Export Promotion Council of India (PHARMEXCIL)

(more…)

SC Side Event to the WHA71, 25 May 2018

Title:                 Side Event to the 71st World Health Assembly, on Access to Medicines: Overcoming Obstacles created by monopolies – Essential to UHC and the 2030 Agenda

Date:                 25 May 2018

Venue:              Room VIII, Palais des Nations, Geneva

Organizers:     Missions of Brazil, India, Morocco, Senegal, and Thailand, with the support of the South Centre

(more…)

Documento de Investigación 85, Mayo 2018

Acceso a medicamentos: experiencias con licencias obligatorias y uso gubernamental – el caso de la Hepatitis C

El acceso a medicamentos está fuertemente condicionado por su precio y por los mecanismos de financiamiento que pueden aplicarse en cada país. […] Un factor determinante en la fijación del precio de los medicamentos es el grado de competencia existente en una particular clase terapéutica, la que a su vez es influenciada por la existencia o no de derechos de propiedad intelectual, como patentes de invención.

(more…)

Policy Brief 46, March 2018

Outcomes of the 142nd session of the WHO Executive Board

The 142nd session of the WHO Executive Board discussed several critical public health issues including a recommendation to the WHA to approve the General Program of Work (GPW), the adoption of important decisions relating to access to medicines and research and development and a draft resolution on the preparation of the UN High Level Meeting on Tuberculosis.

(more…)

Policy Brief 45, October 2017

The Value Added of the United Nations General Assembly High–Level Political Declaration on Antimicrobial Resistance

In September 2016, the United Nations General Assembly (UNGA) in New York held a dedicated meeting to muster strong political commitment for an effective global response to the problem of antimicrobial resistance (AMR). As a result, a High-Level Political Declaration on Antimicrobial Resistance was adopted.

(more…)


0

Your Cart